Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) Sees Large Increase in Short Interest

Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 80,400 shares, a growth of 28.2% from the September 30th total of 62,700 shares. Approximately 1.6% of the company’s shares are short sold. Based on an average daily volume of 40,100 shares, the short-interest ratio is currently 2.0 days.

Hedge Funds Weigh In On Matinas BioPharma

Institutional investors and hedge funds have recently made changes to their positions in the company. Highbridge Capital Management LLC bought a new stake in Matinas BioPharma during the 2nd quarter worth approximately $1,685,000. Towercrest Capital Management bought a new stake in shares of Matinas BioPharma during the second quarter worth $299,000. Finally, Alliance Wealth Management Group bought a new stake in Matinas BioPharma in the 2nd quarter valued at $299,000. Institutional investors and hedge funds own 11.77% of the company’s stock.

Matinas BioPharma Stock Performance

Shares of NYSEAMERICAN MTNB opened at $3.25 on Monday. The stock has a market capitalization of $16.32 million, a PE ratio of -0.59 and a beta of 1.64. Matinas BioPharma has a 1 year low of $2.95 and a 1 year high of $21.50.

Matinas BioPharma (NYSEAMERICAN:MTNB) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02).

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.